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Abstract
AIM: To study the outcomes of primary sclerosing 
cholangitis (PSC) patients with ulcerative colitis (UC) 
undergoing colectomy.
METHODS: We identified 193 patients with PSC and 
UC undergoing colectomy at the Mayo Clinic (Rochester, 
MN, United States), between January 1, 1995 and De-
cember 31, 2008 using a computerized record system. 
Eighty-nine patients were excluded due to unclear diag-
nosis, liver transplantation prior to colectomy, age less 
than 18 years, inadequate follow-up data or known cas-
es of cholangiocarcinoma. We retrospectively reviewed 
data from patient medical records. Clinical information, 
date of colectomy, preoperative and follow-up liver tests 
and pathological findings of the colon were reviewed. 
The Mayo risk score at baseline was calculated to obtain 
survival estimates for up to 4 years of follow-up. The pri-
mary endpoint was defined by the presence of all-cause 
mortality and/or liver decompensation requiring liver 
transplantation. All patients who did not have a clinical 
note on December 31, 2008 were considered as patients 
with an incomplete follow-up unless they reached a 
study endpoint (death or underwent liver transplanta-
tion) prior to that date. The study was approved by the 
Institutional Review Boards of the Mayo Clinic.
RESULTS: Of the 2441 patients with PSC observed in 
this period, 104 patients (4.3%) had UC and underwent 
colectomy and were included. The median age was 
43.2 years, and 67% were male. The leading indica-
tions for colectomy were severe colonic inflammation 
(49%), the presence of colonic dysplasia during routine 
surveillance (42%) and bowel perforation (3%). Twen-
ty-six patients were lost to follow-up after a median du-
ration of 3.9 years. The remaining 78 patients included 
52 patients (66.7%) who were followed for a median 
duration of 5.5 years and 26 patients (33.3%) who de-
veloped primary endpoints including death (n  = 13) or 
underwent liver transplantation (n  = 13) with a median 
follow up of 2.6 years. For the secondary endpoint, the 
liver complications within 1 mo following the colectomy 
were found in 9 patients (8.6%) and included worsen-
ing liver tests (n  = 3), liver failure requiring liver trans-
plantation (n  = 2), acute cholangitis (n  = 3) and right 
hepatic vein thrombosis with hepatic infarct (n  = 1). 
A multivariate logistic analysis demonstrated that only 
lower platelet count and lower albumin level preopera-
tively were significantly associated with more primary 
endpoints (OR = 0.99 and 0.05 respectively). 
CONCLUSION: One third of patients with PSC and UC 
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patients with liver cirrhosis can experience worsening of  
their liver disease after surgery and poor outcomes[10,11]. 
Surgery may lead to severe complications such as de-
compensated liver disease, worsening of  a pre-existing 
decompensation or even death. Very limited information 
exists on the prognosis of  patients with PSC and UC un-
dergoing colectomy[12]. We aimed to assess the outcomes 
and predictors of  outcomes of  PSC patients undergoing 
colectomy at the Mayo Clinic, Rochester, MN, United 
States. 
MATERIALS AND METHODS
This was a retrospective study using a computerized re-
cord system of  patients who had been diagnosed with 
PSC and UC and were undergoing colectomy at the Mayo 
Clinic, Rochester, MN, United States, between January 1, 
1995 and December 31, 2008. PSC was defined as pres-
ent when all the following criteria were met: (1) chronic 
cholestatic disease of  at least six months’ duration; (2) 
elevation of  serum alkaline phosphatase (ALP) levels; 
(3) retrograde, operative, percutaneous or magnetic reso-
nance cholangiography demonstrating intrahepatic and/
or extrahepatic biliary duct obstruction, beading or nar-
rowing consistent with PSC; and (4) exclusion of  second-
ary sclerosing cholangitis or other causes of  cholestatic 
liver diseases[3]. 
A diagnosis of  PSC was made using the Hospital In-
ternational Classification of  Disease Adaptation (HICDA) 
codes of  05760310. A diagnosis of  IBD was based on 
the following HICDA codes: cholangitis, sclerosing 
(05760310); disease, Crohn’s, nos (05630110); enteritis, re-
gional, nos (05630111); ileitis (regional)-see also enteritis 
(05630112); colitis, Crohn’s (05630113); disease, Crohn’
s, recurrent (05630120); enteritis, regional, recurrent 
(05630121); colitis, ulcerative, chronic-cuc (05631110); 
colitis, ulcerative, nos (05631120); colitis, thrombo-
ulcerative (05631121); colitis, ulcerative, acute (05631130); 
colitis, granulomatous (05632110); disease, granuloma-
tous, colon (05632111); disease, inflammatory bowel, nos 
(05639212). HICDA is an adaptation of  the International 
Classification of  Diseases (ICD)-8 for hospital morbidity, 
which was used at Mayo Clinic to maintain continuity of  
the Medical Index and the Rochester Epidemiology Proj-
ect for on-going longitudinal studies[13]. Of  the 2441 pa-
tients with PSC, we identified 193 PSC patients with IBD 
(7.9%) who had undergone colectomy and retrospectively 
reviewed data from their medical records. 
We retrospectively reviewed data from the medical 
records. A detailed history and physical examination was 
recorded by a health care provider using standardized 
protocols. Clinical information, date of  colectomy, preop-
erative and follow-up liver tests and pathological findings 
of  the colon were reviewed. The Mayo risk score at base-
line was calculated to obtain survival estimates through 
up to 4 years of  follow-up. The Mayo risk score calcula-
tions can be accessed from the web site: http://www.
mayoclinic.org/gi-rst/mayomodel3.html, and the MELD 
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undergoing colectomy died or underwent liver trans-
plantation within 2.6 years. PSC patients with lower 
platelet counts and lower albumin levels were signifi-
cantly more likely to have a poorer outcome.
© 2013 Baishideng. All rights reserved.
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Core tip: To study the outcomes of primary sclerosing 
cholangitis (PSC) patients with ulcerative colitis (UC) 
undergoing colectomy. We identified 193 patients with 
PSC and UC undergoing colectomy at the Mayo Clinic 
(Rochester, MN, United States), between January 1, 
1995 and December 31, 2008. Eighty-nine patients 
were excluded. Of the 2441 patients with PSC, 104 
patients (4.3%) had UC and underwent colectomy and 
were included. The median age was 43.2 years. One 
third of patients with PSC and UC undergoing colec-
tomy died or underwent liver transplantation within 
2.6 years. PSC patients with lower platelet counts and 
lower albumin levels were significantly more likely to 
have a poorer outcome.
Treeprasertsuk S, Björnsson E, Sinakos E, Weeding E, Lindor 
KD. Outcome of patients with primary sclerosing cholangitis 
and ulcerative colitis undergoing colectomy. World J Gastroin-
test Pharmacol Ther 2013; 4(3): 61-68  Available from: URL: 
http://www.wjgnet.com/2150-5349/full/v4/i3/61.htm  DOI: http://
dx.doi.org/10.4292/wjgpt.v4.i3.61
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic chole-
static liver disease and is associated with inflammatory 
bowel disease (IBD) in 60%-80% of  patients[1-3]. Ul-
cerative colitis (UC) is more commonly prevalent than 
Crohn’s disease (CD) in patients with PSC[4,5]. The colitis 
associated with PSC has unique findings and is usually 
extensive[4,6]. UC in patients with PSC is associated with 
an increased risk of  colorectal neoplasia compared to 
patients with UC alone (OR = 4.8)[7]. The incidence of  
colorectal neoplasia at 5 years in PSC patients with IBD 
is significantly higher than in patients with UC alone (33% 
vs 13%, P = 0.054; borderline statistical significance by 
unmatched log rank test)[4]. 
A recent study reported that PSC was the third lead-
ing cause (15.4%) of  abnormal liver tests among 545 
patients with underlying IBD undergoing colectomy with 
ileal pouch-anal anastomosis (IPAA), after a transient 
elevation of  liver tests (49%) and fatty liver (15.4%)[8]. 
Another study evaluated the progression of  liver disease 
after proctocolectomy in patients with PSC and UC[9]. Af-
ter proctocolectomy with IPAA, they found that 5 of  30 
patients (16.7%) underwent liver transplantation at inter-
vals of  1 to 11 years[9]. Previous studies have shown that 
model/UNOS modification can be accessed from http://
www.mayoclinic.org/ meld/mayomodel6.html.
Inclusion criteria
We included PSC patients who underwent colectomy and 
had results of  preoperative liver tests and at least one 
post-operatively. Colectomy cases included open or lapa-
roscopic colectomy. All included patients must have had 
at least one follow-up visit after the colectomy. The liver 
tests included total bilirubin, direct bilirubin, albumin, 
alanine aminotransferase (ALT), aspartate aminotransfer-
ase (AST) and ALP levels in the serum.
Exclusion criteria
Of  the 193 patients with PSC and UC undergoing col-
ectomy, we excluded the patients with the followings: 
underwent liver transplantation prior to colectomy, in-
adequate follow-up data, CD, age less than 18 years and 
known cases of  cholangiocarcinoma. 
 
Follow-up data
The primary endpoint was defined as the presence of  all-
cause mortality and/or liver decompensation requiring 
liver transplantation and it has been measured at 1 mo 
and at the end of  follow-up. All causes of  death listed on 
the death certificates or pathological findings (underly-
ing, intermediate, immediate and other major conditions) 
were recorded using the ICD-10 revision. 
The secondary end point was defined as the presence 
of  liver complications post-operatively occurred within 
1 mo which included ascites, variceal bleeding, clinical 
hepatic encephalopathy or liver failure and required hos-
pitalization. The worsening liver tests were defined as 
increases in AST, ALT or total bilirubin to at least 2-fold 
greater than the baseline values. Other information in-
cluding the the length of  hospital stay and general post-
operative complications were recorded.
All patients who did not have a clinical note on De-
cember 31, 2008 (the end of  follow up in this study) 
were considered as patients with incomplete follow up 
unless they developed an endpoint (death or underwent 
liver transplantation) prior to that date. The study was ap-
proved by the Institutional Review Boards of  the Mayo 
Clinic, and all participants provided permission for their 
medical information to be used for research.
Statistical analysis
Statistical analyses were performed with SPSS version 
15.0 software. Subjects were categorized by the presence 
or absence of  primary endpoints. Continuous variables 
were presented as the mean ± SD or median [interquartile 
range (IQR)] as appropriate. Comparisons between the 
two groups were performed using independent t tests if  
values were normally distributed or by the Wilcoxon rank 
sum test if  the distribution was not normal. Categorical 
data were presented as numbers (percentage) and were 
compared by Fisher’s exact test or the χ 2 test where ap-
propriate. All tests were two sided, and the chosen level 
of  significance was P < 0.05. A logistic regression analy-
sis was used to identify factors significantly associated 
with the presence of  primary endpoints in PSC patients 
with UC undergoing colectomy. Only variables with a P 
value < 0.1 in a univariate analysis were included in the 
multivariate analysis. We estimated receiver operating 
characteristic (ROC) curves of  related variables for de-
tection of  the primary endpoints in patients with PSC to 
maximize the area under the curve (AUC). 
RESULTS
Clinical features at presentation 
Of  the 2441 patients with PSC, 193 patients with PSC 
and UC undergoing colectomy were identified. Eighty-
nine patients were excluded due to liver transplantation 
prior to colectomy (n = 30), inadequate follow-up data 
(n = 35), CD (n = 16), age less than 18 years (n = 6) and 
known cases of  cholangiocarcinoma (n = 2). The remain-
ing of  104 patients (4.3% of  2441 PSC patients) were 
included in this study. The median age was 43.2 years, 
and 67% were male. The demographic and biochemical 
data of  the 104 patients are shown in Table 1. The me-
dian (IQR) Mayo risk score was -0.05 (-0.7, 1.1) while the 
median (IQR) MELD score was 9 (6, 12). The leading 
indications for colectomy were severe colonic inflamma-
tion (49%), colonic dysplasia observed during routine 
surveillance (42%) and bowel perforation (3%). Most 
of  the preoperative total bilirubin, direct bilirubin and 
albumin levels were within normal range, while the mean 
ALP value was two fold greater than normal.
Clinical outcomes 
Table 1 summarizes the postoperative clinical outcomes 
of  the 104 patients with a median (IQR) hospital stay of  
7 d (6, 11). Of  104 patients with PSC and UC, 26 were 
lost to follow-up after a median duration of  3.9 years. 
The remaining 78 patients included 52 patients (66.7%) 
who continued follow up, with a median duration of  5.5 
years, and 26 patients developed primary endpoints in-
cluding death or underwent liver transplantation (33.3%), 
with a median follow up of  2.6 years (Figure 1). The 
causes of  death of  the 13 patients were liver-related 
complications: hepatocellular carcinoma, hepatic renal 
syndrome and/or liver failure (n = 4), metastatic cancer 
to the liver (n = 5), acute cholangitis (n = 1), amyloidosis 
(n = 1) and unknown causes (n = 2). Two patients died at 
10 and 20 d following colectomy. For the secondary end-
point, the liver complications within 1 mo following the 
colectomy were found in 9 patients (8.6%) and included 
worsening liver tests (n = 3), liver failure requiring liver 
transplantation (n = 2), acute cholangitis (n = 3) and right 
hepatic vein thrombosis with hepatic infarct (n= 1) (Table 
2). General postoperative complications were found in 
36 patients (34.6%) within 1 mo. The most common 
complications were anemia or blood loss requiring blood 
transfusion (n = 11; 10.6%), intra-abdominal abscess re-
quiring drainage (n = 4; 3.8%), acute bowel obstruction 
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requiring re-exploration (n = 4; 3.8%), bowel ileus (n = 4; 
3.8%), high ileostomy output (n = 3; 2.8%), wound infec-
tion or delayed wound healing (n = 3; 2.8%) and other 
complications (n = 8; 7.7%) including urinary retention (n 
= 3), fever with unknown causes (n = 2), acute pancreati-
tis (n = 1), abdominal pain with unknown causes (n = 1) 
and portal vein thrombosis (n = 1). 
By the end of  the follow-up of  patients with PSC and 
UC who underwent colectomy, 13 patients developed 
colorectal cancer (15%) and 13 patients (16.7%) were 
diagnosed with other malignancies. The primary location 
of  the malignancies were cholangiocarcinoma (n = 6), 
hematologic malignancy (n = 4), gallbladder cancer (n = 
1), hepatocellular carcinoma (n = 1) and intradural extra-
medullary spinal cord tumor (n = 1). Colonic dysplasia 
was found in 21 patients (21.2%) including low-grade 
dysplasia in 16 and high grade dysplasia in 5.
Predictors for primary endpoints (death or undergoing 
liver transplantation)
Table 3 shows the comparison of  clinical characteristics of  
the 78 PSC patients with UC who underwent colectomy 
based on the presence of  primary endpoints. Table 4 shows 
the results of  3 models from the multivariate analysis 
to identify the best-fit model for predictors of  primary 
endpoints. Model 1 was the best-fit model, which found 
that only a higher platelet count and higher albumin level 
preoperatively were significantly associated with fewer 
primary endpoints (OR = 0.99 and 0.05, respectively; P < 
0.05). Using the ROC curves for the detection of  primary 
endpoints, we found that a preoperative platelet count of  
194 × 109/L was the best cutoff  value based on a sensi-
tivity of  46%, a specificity of  88.5%, a positive predictive 
value (PPV) of  66.7%, and an negative predictive value 
(NPV) of  76.7% with an AUC of  0.67. The best cutoff  
value of  the preoperative albumin level for the presence 
of  primary endpoints was 3.7 g/dL with a sensitivity of  
73%, a specificity of  82%, a PPV of  70%, an NPV of  
84%, and an AUC of  0.80.
Figure 2 shows the survival curve of  the 104 pa-
tients with PSC and UC who underwent colectomy. 
The smooth line represents median survival estimates 
calculated from the Mayo risk scores at baseline, and the 
stepped line corresponds to survival per the Kaplan-
Meier method. The two survival curves were found to 
significantly differ over this time period (P = 0.01) which 
indicated that PSC patients with UC who underwent col-
ectomy died or required liver transplantation more often 
than those PSC patients with UC who had no colectomy 
regarding to the same baseline calculated Mayo risk 
scores.
DISCUSSION
Our study indicates that one third of PSC patients with 
UC who underwent colectomy died or required liver 
transplantation within an average interval of  2.6 years. 
This result was similar to a previous study from the 
Cleveland Clinic showing that 38% of  cirrhotic patients 
with PSC who underwent colectomy experienced early 
64 August 6, 2013|Volume 4|Issue 3|WJGPT|www.wjgnet.com
  Patient characteristics1 Total (n  = 104) Patients who con-
tinued follow-up or 
developed primary 
endpoints (n  = 78)
  Baseline characteristics data
     Age at colectomy (yr)       43 (30-53)         42 (28-52)
     Gender, male       70 (67)         56 (72)
     Race, Caucasian       98 (94)         76 (97)
     Presence of advanced liver 
     fibrosis at baseline
      27 (32)         24 (39)
     Mayo risk score at baseline   -0.05 (-0.7, 1.1)   -0.001 (-0.8, 1.4)
     BMI (kg/m2)       25 (22.6, 28.6)      24.7 (22, 27.4)
     Previous use of 
     immunosuppressive drugs 
      38 (36.5)         29 (37)
     History of receiving 
     ursodeoxycholic acid
      33 (31.7)         26 (33.3)
     Diabetes mellitus or impaired 
     glucose tolerance
        7 (7)           6 (7.6)
     History of current smoking         2 (2)           2 (2.6)
     Indication for colectomy
        Severe colonic inflammation       51 (49)         37 (47)
        Colonic dysplasia       44 (42)         36 (46)
        Bowel perforation         3 (2.8)           3 (3.8)
        Other indications         6 (5.7)           2 (2.6)
  Laboratory tests at baseline  
     ALT (< 40 U/L)       70 (43, 113)         73 (43, 135)
     AST (< 40 U/L)       50 (30, 96)         55 (32, 100)
     Albumin (g/dL)      3.9 (3.5, 4.2)        3.9 (3.5, 4.2)
     Total bilirubin (mg/dL)      0.7 (0.5, 1.5)        0.8 (0.5, 1.9)
     Direct bilirubin (mg/dL)      0.2 (0.1, 0.7)        0.3 (0.1, 0.9)
     ALP (U/L)     359 (194, 657)       385 (197, 839)
     Glucose (mg/dL)       93 (86, 106)      93.5 (86, 107)
     Creatinine (mg/dL)      1.0 (0.9, 1.1)        1.0 (0.9, 1.1)
     CA 19-9 (normal < 55 U/mL)    17.2 (8.8, 51)      16.8 (8.5, 51)
     Platelet (× 109/L)     289 (201, 350)       289 (205, 351)
     INR         1 (0.9, 1.1)           1 (0.9, 1.1)
  Clinical outcomes at the end 
  of follow-up 
     Undergoing Ileal pouch-anal 
     anastomosis 
      78 (75)         58 (74)
     Length of hospital stay (d)         7 (6, 11)           8 (5, 12)
  New diagnosis of malignancy 
  after colectomy
      32 (30.8)         26 (33.4)
     Colorectal cancer       19 (18.3)         13 (16.7)
     Other malignancy       13 (12.5)         13 (16.7)
  Pathological findings
     Colonic inflammation       62 (60)         45 (57.7)
     Presence of colonic dysplasia       24 (23)         21 (27)
     Colon cancer       19 (18.3)         12 (15.4)
     Post-operative general 
     complications within 1 mo
      36 (34.6)         34 (43.6)
     Post-operative liver 
     complications within 1 mo
        9 (8.7)2           9 (11.5)
  Results of follow-up
     All-cause mortality       13 (12.5)         13 (16.7)
     Liver transplantation       13 (12.5)         13 (16.7)
     Continued follow-up       52 (50)         52 (66.6)
     Lost to follow-up       13 (25.0) -
Table 1  Baseline characteristics data, laboratory tests and 
clinical outcomes of 104 patients with primary sclerosing 
cholangitis and ulcerative colitis who underwent colectomy
1Median (interquartile range; IQR) or n (%); 2Including worsening liver 
tests (n = 3), liver failure requiring liver transplantation (n = 2), acute chol-
angitis (n = 3) and right hepatic vein thrombosis with hepatic infarct (n = 1). 
BMI: Body mass index; ALT: Alanine transaminase; AST: Aspartate ami-
notransferase; ALP: Alkaline phosphatase; CA 19-9: Cancer antigen 19-9.
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Figure 1  Outcomes of 104 patients with primary sclerosing cholangitis and ulcerative colitis who underwent colectomy. IBD: Inflammatory bowel disease; 
PSC: Primary sclerosing cholangitis; HICDA: Hospital international classification of disease adaptation.
  Case, Sex Age at 
colectomy 
(yr)
Presence of 
advanced 
liver fibrosis
Pathological find-
ings in the colon
Blood loss 
requiring 
transfusion
Liver complications Other 
complications
Length of 
stay (d)
Presence of primary 
endpoints
Duration of 
follow up 
(yr)
  1, M 28 Yes Moderate 
inflammation
No Worsening liver tests Abdominal pain, 
Dehydration
18 No     8.5
  2, M 28 Yes Transverse colon 
cancer grade 3/4 
T3N2
Yes; 2 units Worsening liver tests High ileostomy 
output
15 Death; colon cancer 
metastasis to liver
    1.2
  3, F 52 Yes Mild 
inflammation
No Worsening liver tests Delayed wound 
healing, Blood loss
 8 Death; liver failure     0.3
  4, M 32 No Moderate 
inflammation
No Acute cholangitis None  9 Liver transplant     1.1
  5, M 33 Yes Moderate 
inflammation
No Acute cholangitis None  6 No     8.3
  6, F 54 No Mild 
inflammation
Yes; 6 units Liver failure Severe blood loss, 
shock
 8 Liver transplant; 
liver failure
    0.3
  7, F 21 Yes Necrotized 
distal ileum 
with perforation
Yes; 9 units Liver failure DIC, Respiratory 
failure, GI-bleeding
30 Death; liver failure    0.03 (12 d)
  8, F 21 No Moderate 
inflammation
Yes; 2 units SMV and hepatic 
vein thrombosis
Anemia, 15 Death; liver failure     8
  9, M 41 No Moderate 
inflammation
No Acute cholangitis Wound infection 10 No     3.6
Table 2  Nine patients with primary sclerosing cholangitis and ulcerative colitis who underwent colectomy had worsening liver tests 
postoperatively
M: Male; F: Female; DIC: Disseminated intravascular coagulation; HCC: Hepatocellular carcinoma; SMV: Superior mesenteric vein.
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Of the 2441 patients with PSC, 193 Patients with an HICDA code of ulcerative colitis or 
Crohn's disease and 05760-31-0 (PSC) and colectomy between January 01, 1995 and 
December 31, 2008 were identified 
Excluded 89 patients; 
  Liver transplantation before colectomy (n  = 30) 
  Incomplete follow up data (n  = 21) 
  Crohn’s disease (n  = 16)
  Indefinite diagnosis of PSC or IBD (n  = 14)
  Age < 18 yr (n  = 6)
  Known cases of cholangiocarcinoma before colectomy (n  = 2)
104 of 2441 patients with PSC (4.3%) were included, and data 
were extracted from medical records
No patients developed liver compli-
cations within 4 wk postoperative.
PSC patients lost to follow-up (n  = 26; 
25% of 104 patients) with a median 
duration of 3.9 yr
PSC patients with a primary end point (n  = 26; 25% 
of 104 patients) over a median duration of 2.6 yr
3/52 patients (6%) 
developed liver com-
plications within 4 wk 
postoperative.
6/26 patients (23%) 
developed liver 
complications within 4 wk 
postoperative.
PSC patients who continued follow-
up (n  = 52; 50% of 104 patients) 
over a median duration of 5.5 yr
Death (n  = 13 of 78; 16.7%)
Liver transplantation 
 (n  = 13 of 78; 16.7%)
postoperative death compared to 0% of  non-cirrhotic 
patients[14]. However, the previous study was limited by 
the small number of  included patients with PSC who 
underwent colectomy (n = 24) and the need for a preop-
erative diagnosis of  cirrhosis. The present study builds 
on previous reports from our center regarding the risk of  
colectomy in patients with PSC and UC[15,16].
However, three previous studies reported that procto-
colectomy had little effect on the progression of  liver dis-
ease in patients with PSC and UC and there was no sig-
nificant difference in the survival of  patients undergoing 
colectomy compared to unoperated patients[17-20]. A study 
from England showed that PSC patients who underwent 
colectomy prior to or concurrent with liver transplan-
tation (n = 17) had a mortality rate of  12%, and they 
concluded that colectomy was a relatively safe procedure 
and believed that considering colectomy pre-, during, or 
shortly after liver transplantation in selected patients with 
risk factors for colorectal cancer would reduce the risk 
of  colorectal cancer[19]. The low colectomy rate of  4% 
in our study might reflect the usually quiescent colitis in 
PSC. The majority of  our patients were the large duct 
PSC which might have an impact on the poorer outcome 
from liver complications[9,21,22]. Recently, the outcomes 
after elective colectomy in patients with cirrhosis were 
examined and showed that cirrhotic patients undergoing 
colectomy had a 3.7-fold increased risk of  death (HR of  
3.7; 95%CI: 2.6-5.2)[23]. The in-hospital mortality (6%), 
length of  stay (9 d), and total expenses of  cirrhotic pa-
tients were significantly higher than for those without cir-
rhosis[23,24].
Our results showed that a lower platelet count and 
lower albumin level preoperatively were associated 
with poorer outcomes. Thus, using simple preoperative 
blood test screening may provide useful information 
for monitoring patients pre-operatively. The timing of  
colectomy is an important issue. Recently, a study from 
Italy[20] showed that eight of  16 patients with PSC and 
UC post-liver transplantation had active colitis despite 
immunosuppressive medications with a median interval 
from liver transplantation to colectomy of  6.5 years. Few 
studies showed that the colitis condition in PSC patients 
with UC remained inactive or under controlled of  at least 
60% of  cases after orthotopic liver transplantation[25,26]. 
Another studied revealed that liver transplantation for 
PSC independently reduced the need for colectomy (HR 
= 0.43; 95%CI: 0.25-0.75; P = 0.003)[11] Additionally, the 
presence of  colon carcinoma and high grade dysplasia 
were more frequent in the non liver transplantation group 
and this group of  patient had increased inflammation 
of  the colonic mucosa at histology (P = 0.011)[10]. Thus, 
the patients with severe progressive PSC requiring liver 
transplantation should proceeded for supportive care of  
colitis and listed for liver transplantation which might 
reduced the disease activity of  UC and the need for col-
ectomy[10,11]. 
About 17% of  our PSC patients with UC developed 
colorectal cancer, which was similar to a previous report 
from England showing that the cumulative risks of  de-
veloping colorectal cancer in patients with an intact colon 
and IBD were 14% and 17% after 5 and 10 years, respec-
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  Clinical characteristics1 Without pri-
mary endpoints 
(n  = 52)
With primary 
endpoints 
(n  = 26)
P  value2
  Gender, %female    11 (21)    11 (42)  0.052
  Age at colectomy (yr) 38.7 (27.8, 51.6) 45.8 (29.4, 52) 0.40
  Presence of advanced liver 
  fibrosis 
   12 (23)    12 (46)  0.032
  Pre-operative Mayo risk score  -0.1 (-0.9, 0.9)   1.3 (-0.2, 2.2)  0.012
  Pre-operative MELD score      7 (6, 9)    14 (11, 18) < 0.0012
  History of anemia or blood 
  loss requiring a post-operative 
  blood transfusion within 1 mo 
     4 (7.7)      7 (27)  0.022
  Post-operative liver 
  complications within 1 mo 
     3 (5.8)      6 (23)  0.022
  Length of hospital stay (d)      7 (5, 10)      9 (7, 15) 0.07
  Hemoglobin (g/dL) 13.1 (11.9, 14.4) 10.8 (9.8, 13.1) < 0.0012
  Platelet count (× 109/L)  296 (247, 357)  244 (126, 337)  0.022
  INR   0.9 (0.9, 1.0)   1.1 (1.1, 1.3) < 0.0012
  Total bilirubin (mg/dL)   0.7 (0.5, 1.3)   2.3 (0.6, 5.0)    0.0012
  Direct bilirubin (mg/dL)   0.2 (0.1, 0.4)   0.9 (0.2, 3.5)    0.0022
  ALP (U/L)  352 (180, 494)  709 (276, 1232)    0.0032
  AST (U/L)    44 (31, 90)    80 (36, 129) 0.09
  Albumin (g/dL)   4.1 (3.4, 4.3)   3.5 (3.3, 3.9) < 0.0012
  Duration of follow up from 
  colectomy to the last 
  follow-up (yr)
  5.5 (3.8, 8.8)   2.6 (0.8, 5.6)    0.0072
Table 3  A comparison of the clinical characteristics of 78 pa-
tients with primary sclerosing cholangitis and ulcerative colitis 
who underwent colectomy categorized by the presence or 
absence of primary endpoints
1Median [interquartile range (IQR)] or n (%); 2P value < 0.05 for primary 
sclerosing cholangitis patients with or without primary endpoints and 
those variables with a P value < 0.1 in a univariate analysis were included 
in the multivariate analysis. AST: Aspartate aminotransferase; ALP: Alka-
line phosphatase; MELD: Model for End-Stage Liver Disease.
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Figure 2  The survival curves of 104 patients with primary sclerosing 
cholangitis and ulcerative colitis undergoing colectomy. The smooth line 
represents the median survival estimate calculated from the Mayo risk scores 
at baseline, and the stepped line corresponds to survival calculated using the 
Kaplan-Meier method. The two survival curves were found to significantly differ 
over this time period (P = 0.01) which indicated that primary sclerosing chol-
angitis (PSC) patients with ulcerative colitis who underwent colectomy died or 
required liver transplantation more often than those PSC patient with ulcerative 
colitis who had no colectomy regarding to the same baseline calculated Mayo 
risk scores.
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tively[19]. Recent study showed that the colonic neoplasms 
that developed in PSC-UC patients were spread through-
out the colon on colonoscopy and they were found 
predominantly on right sided colon[5]. Thus, surveillance 
colonoscopy and biopsies should be performed in pa-
tients with PSC and UC at 1-year to 2-year intervals[3].
The main strengths of  our study are the inclusion of  
a large number of  PSC patients with PSC and UC and 
the available clinical data and pathological findings, which 
were useful for outcome assessment. However, our study 
is limited by its retrospective nature in a tertiary center, 
and it contains data derived from multiple physicians 
from 1995 to 2008, which may have resulted in a selec-
tion bias. Additionally, surgeons excluded the colectomy 
procedure for all patients with poor liver conditions. 
Second, we included all PSC patients who underwent col-
ectomy and had results from preoperative liver tests and 
at least one post-operative test, which may explain the 
small number of  patients with liver complications. Thus, 
further multicenter prospective studies of  post-operative 
liver complications and poor outcomes in patients with 
PSC and UC undergoing colectomy should be performed 
to provide clearer guidance for the selection of  patients 
to be referred for a liver transplantation and colectomy 
rather than colectomy alone.
Unfortunately, we had to exclude a number of  pa-
tients (10%) who had incomplete data because they were 
lost to follow-up. Additionally, the Mayo risk score and 
MELD score could not be calculated annually from our 
retrospective data therefore the colectomy might changed 
the progression of  the PSC severity which cannot be 
concluded. Last, we had only a small number of  patients 
with liver complications, and we can therefore not draw 
a firm conclusion regarding the association between liver 
complications and poor outcomes. 
In conclusion, one third of PSC patients with UC 
who underwent colectomy died or underwent liver trans-
plantation within an average interval of  2.6 years. PSC 
patients with advanced liver fibrosis (lower platelet count 
and lower albumin level) and UC who underwent colec-
tomy were associated with significantly poorer outcomes. 
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Background
The colitis associated with primary sclerosing cholangitis (PSC) has unique 
findings and is usually extensive. Ulcerative colitis (UC) in patients with PSC is 
associated with an increased risk of colorectal neoplasia compared to patients 
with UC alone. Previous studies have shown that patients with liver cirrhosis 
can experience worsening of their liver disease after surgery and poor out-
comes. Surgery may lead to severe complications such as decompensated 
liver disease, worsening of a pre-existing decompensation or even death. Very 
limited information exists on the prognosis of patients with PSC and UC under-
going colectomy. 
Research frontiers
Authors aimed to assess the outcomes and predictors of outcomes of PSC pa-
tients undergoing colectomy at the Mayo Clinic, Rochester, MN, United States.
Innovations and breakthroughs
One third of patients with PSC and UC undergoing colectomy died or under-
went liver transplantation within 2.6 years. PSC patients with lower platelet 
counts and lower albumin levels were significantly more likely to have a poorer 
outcome.
Applications
PSC patients with UC who underwent colectomy died or required liver transplan-
tation more often than those PSC patients with UC who had no colectomy regard-
ing to the same baseline calculated Mayo risk scores.
Terminology
The primary endpoint was defined as the presence of all-cause mortality and/or 
liver decompensation requiring liver transplantation and it has been measured 
at 1 mo and at the end of follow-up. All causes of death listed on the death 
certificates or pathological findings (underlying, intermediate, immediate and 
other major conditions) were recorded using the International Classification of 
Diseases-10 revision. The secondary end point was defined as the presence 
of liver complications post-operatively occurred within 1 mo which included 
ascites, variceal bleeding, clinical hepatic encephalopathy or liver failure and 
required hospitalization To concisely and accurately describe, define or explain 
the specific, unique terms that are not familiar to majority of the readers, but are 
essential for the readers to understand the article.
Peer review
Few studies showed that the colitis condition in PSC patients with UC remained 
inactive or under controlled of at least 60% of cases after orthotopic liver 
transplantation. Another studied revealed that liver transplantation for PSC 
independently reduced the need for colectomy. Additionally, the presence of 
colon carcinoma and high grade dysplasia were more frequent in the non liver 
transplantation group and this group of patient had increased inflammation of 
the colonic mucosa at histology. Thus, the patients with severe progressive 
PSC requiring liver transplantation should proceeded for supportive care of coli-
tis and listed for liver transplantation which might reduced the disease activity of 
UC and the need for colectomy. 
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